fluoxetine has been researched along with Somatoform Disorders in 29 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Somatoform Disorders: Disorders having the presence of physical symptoms that suggest a general medical condition but that are not fully explained by another medical condition, by the direct effects of a substance, or by another mental disorder. The MEDICALLY UNEXPLAINED SYMPTOMS must cause clinically significant distress or impairment in social, occupational, or other areas of functioning. In contrast to FACTITIOUS DISORDERS and MALINGERING, the physical symptoms are not under voluntary control. (APA, DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)." | 7.72 | Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Sklarsky, KG; Summergrad, P, 2004) |
| "The recent clinical studies on hypericum extract support the present indications for its use in mild to moderate depression and depressive episodes." | 4.84 | [New developments in hypericum extracts: data on efficacy and interactions]. ( Kraft, K, 2007) |
| "In the present study we assessed the relationship between somatic symptoms and the time to onset of clinical response to fluoxetine in patients with major depressive disorder (MDD)." | 3.72 | Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. ( Alpert, JE; Fava, M; Iosifescu, DV; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Sklarsky, KG; Summergrad, P, 2004) |
| "The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg)." | 3.72 | Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. ( Alpert, JE; Fava, M; Hughes, ME; Nierenberg, AA; Papakostas, GI; Petersen, T, 2004) |
| "One hundred and three patients of major depressive disorders were observed." | 2.79 | Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period. ( Gu, S; Guo, J; Luo, H; Qu, W; Tang, Q, 2014) |
| "Patients suffering from major depressive disorder (MDD) have been reported to have substantial long-lasting limitations in multiple domains of health-related quality of life (HRQoL)." | 2.78 | Health-related quality of life and symptom severity in Chinese patients with major depressive disorder. ( Cao, Y; Li, W; Luo, X; Malison, RT; Shen, J; Zhang, Y, 2013) |
| "Fluoxetine has a better analgesic effect than a placebo in treating persistent somatoform pain disorder, and is considered a safe treatment; its analgesic effect may be related to an antidepressant effect." | 2.74 | A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. ( Li, CB; Li, QW; Lu, Z; Luo, YL; Wu, WY; Zhang, MY, 2009) |
| "Pimozide was not more effective than placebo: two (18." | 2.71 | Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. ( Phillips, KA, 2005) |
| "Fluoxetine was generally well tolerated." | 2.70 | A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. ( Albertini, RS; Phillips, KA; Rasmussen, SA, 2002) |
| "Major depressive disorder is a medical condition that includes abnormalities of affect and mood, cognition, and physical functioning." | 2.42 | The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. ( Fava, M, 2003) |
| "This case report describes numbness and dysmorphic symptoms in the upper facial area associated with fluoxetine." | 1.32 | Serotonin reuptake inhibitor induced sensory disturbances. ( Praharaj, SK, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 7 (24.14) | 18.2507 |
| 2000's | 17 (58.62) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Subramanian, K | 1 |
| Manohar, H | 1 |
| Menon, V | 1 |
| Cao, Y | 1 |
| Li, W | 1 |
| Shen, J | 1 |
| Malison, RT | 1 |
| Zhang, Y | 1 |
| Luo, X | 1 |
| Qu, W | 1 |
| Gu, S | 1 |
| Luo, H | 1 |
| Tang, Q | 1 |
| Guo, J | 1 |
| Papakostas, GI | 3 |
| McGrath, P | 1 |
| Stewart, J | 1 |
| Charles, D | 1 |
| Chen, Y | 1 |
| Mischoulon, D | 2 |
| Dording, C | 1 |
| Fava, M | 5 |
| Phillips, KA | 5 |
| Kelly, MM | 1 |
| Ipser, JC | 1 |
| Sander, C | 1 |
| Stein, DJ | 1 |
| Kendrick, T | 1 |
| Chatwin, J | 1 |
| Dowrick, C | 1 |
| Tylee, A | 1 |
| Morriss, R | 1 |
| Peveler, R | 1 |
| Leese, M | 1 |
| McCrone, P | 1 |
| Harris, T | 1 |
| Moore, M | 1 |
| Byng, R | 1 |
| Brown, G | 1 |
| Barthel, S | 1 |
| Mander, H | 1 |
| Ring, A | 1 |
| Kelly, V | 1 |
| Wallace, V | 1 |
| Gabbay, M | 1 |
| Craig, T | 1 |
| Mann, A | 1 |
| Luo, YL | 1 |
| Zhang, MY | 1 |
| Wu, WY | 1 |
| Li, CB | 1 |
| Lu, Z | 1 |
| Li, QW | 1 |
| Kushwaha, V | 1 |
| Chadda, RK | 1 |
| Mehta, M | 1 |
| al-Adawi, S | 1 |
| Martin, R | 1 |
| al-Naamani, A | 1 |
| Obeid, Y | 1 |
| al-Hussaini, A | 1 |
| Petersen, TJ | 1 |
| Iosifescu, DV | 1 |
| Summergrad, P | 1 |
| Sklarsky, KG | 1 |
| Alpert, JE | 3 |
| Nierenberg, AA | 2 |
| Petersen, T | 1 |
| Hughes, ME | 1 |
| Greco, T | 1 |
| Eckert, G | 1 |
| Kroenke, K | 1 |
| Praharaj, SK | 1 |
| Farabaugh, A | 1 |
| Wu, SL | 1 |
| Mascarini, A | 1 |
| Tossani, E | 1 |
| Kraft, K | 1 |
| Han, C | 1 |
| Pae, CU | 1 |
| Lee, BH | 1 |
| Ko, YH | 1 |
| Masand, PS | 1 |
| Patkar, AA | 1 |
| Jung, IK | 1 |
| Atala, KD | 1 |
| Albertini, RS | 2 |
| Brandenburg, S | 1 |
| Tuynman-Qua, H | 1 |
| Verheij, R | 1 |
| Pepplinkhuizen, L | 1 |
| Small, GW | 1 |
| Hamilton, SH | 1 |
| Bystritsky, A | 1 |
| Meyers, BS | 1 |
| Nemeroff, CB | 1 |
| Cleare, AJ | 1 |
| Wessely, SC | 1 |
| Symonds, A | 1 |
| Ferrando, SJ | 1 |
| Goldman, JD | 1 |
| Charness, WE | 1 |
| Dominguez, RA | 1 |
| Puig, A | 1 |
| Rasmussen, SA | 1 |
| Hollander, E | 1 |
| Liebowitz, MR | 1 |
| Winchel, R | 1 |
| Klumker, A | 1 |
| Klein, DF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529] | Phase 4 | 140 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Silymarin Treatment of Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled, Cross-Over Study[NCT02843451] | Phase 2 | 0 participants (Actual) | Interventional | 2016-10-31 | Withdrawn (stopped due to Focus on other studies) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fluoxetine and Somatoform Disorders
| Article | Year |
|---|---|
Pharmacotherapy and psychotherapy for body dysmorphic disorder.
Topics: Adrenergic Uptake Inhibitors; Body Image; Clomipramine; Cognitive Behavioral Therapy; Desipramine; F | 2009 |
The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Norepi | 2003 |
[New developments in hypericum extracts: data on efficacy and interactions].
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bridg | 2007 |
Treatment of body-dysmorphic disorder with serotonin reuptake blockers.
Topics: Adult; Body Image; Clomipramine; Diagnosis, Differential; Female; Fluoxetine; Humans; Male; Middle A | 1989 |
15 trials available for fluoxetine and Somatoform Disorders
| Article | Year |
|---|---|
Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Asian People; China; Depressive Disorder, M | 2013 |
Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
Topics: Adult; Benzodiazepines; Depressive Disorder, Major; Drug Administration Schedule; Drug Combinations; | 2014 |
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depress | 2008 |
Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder.
Topics: Double-Blind Method; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Soma | 2009 |
Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care
Topics: Adolescent; Adult; Aged; Comorbidity; Cost-Benefit Analysis; Depression; Female; Fluoxetine; Humans; | 2009 |
A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents, Second-Generation; Depression; Double-Bl | 2009 |
Psychotherapeutic intervention in somatisation disorder: results of a controlled study from India.
Topics: Adult; Breathing Exercises; Combined Modality Therapy; Female; Fluoxetine; Humans; India; Male; Prob | 2013 |
The outcome of physical symptoms with treatment of depression.
Topics: Depressive Disorder; Female; Fluoxetine; Follow-Up Studies; Health Status; Health Surveys; Humans; M | 2004 |
Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
Topics: Adult; Antipsychotic Agents; Delusions; Double-Blind Method; Drug Therapy, Combination; Female; Fluo | 2005 |
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety; D | 2005 |
Olanzapine augmentation of fluoxetine in body dysmorphic disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; Female | 2005 |
Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Health St | 2008 |
Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group.
Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fl | 1995 |
Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms.
Topics: 1-Naphthylamine; Acquired Immunodeficiency Syndrome; Adaptation, Psychological; Adult; Depressive Di | 1997 |
A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
Topics: Adult; Double-Blind Method; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Sele | 2002 |
10 other studies available for fluoxetine and Somatoform Disorders
| Article | Year |
|---|---|
Family accommodation in somatoform disorders-its effects on diagnosis and management: A case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude to Health; Caregivers; Diagnosis, Differen | 2017 |
Body dysmorphic disorder in Oman: cultural and neuropsychological findings.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Image; Cultural Characteristics; Diagnosis, Di | 2001 |
Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.
Topics: Adult; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Humans; Male; Personality Inventory | 2004 |
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Prospective Studies; S | 2004 |
Serotonin reuptake inhibitor induced sensory disturbances.
Topics: Adult; Fluoxetine; Humans; Hypesthesia; Male; Selective Serotonin Reuptake Inhibitors; Somatoform Di | 2004 |
Case study: body dysmorphic disorder in adolescents.
Topics: Adolescent; Body Image; Depressive Disorder; Female; Fluoxetine; Humans; Male; Phobic Disorders; Psy | 1995 |
Treatment of premenstrual syndrome with fluoxetine: an open study.
Topics: Adult; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Personality Inventory; Pr | 1993 |
Fluoxetine and chronic fatigue syndrome.
Topics: Antidepressive Agents, Second-Generation; Fatigue Syndrome, Chronic; Fluoxetine; Humans; Somatoform | 1996 |
The mind and the butt.
Topics: Adult; Buttocks; Combined Modality Therapy; Depression, Postpartum; Female; Fluoxetine; Humans; Obse | 1996 |
Olfactory reference syndrome responds to clomipramine but not fluoxetine: a case report.
Topics: Adult; Clomipramine; Comorbidity; Delusions; Depressive Disorder; Fluoxetine; Humans; Male; Obsessiv | 1997 |